VIVI:CSE, TempraMed Technologies Ltd.
VIVI stock overview
TempraMed Technologies Ltd. (VIVI:CSE) closed at $0.310 on November 13, 2026,
down 4.62% on the day.
The stock trades 77.9% below its 52-week high of $1.40
and 29.2% above its 52-week low of $0.240.
Over the past year, it lost 61.3%.
TempraMed Technologies Ltd. is part of the Life Sciences sector.
Key figures
- Price
- $0.310
- Day change
- -4.62%
- Volume
- 17,812
- Average volume
- 10,273
- Market cap
- 24M+
- 52-week range
- $0.240 – $1.40
- 50-day average
- $0.399
- 200-day average
- $0.615
Price action over the past year
In 252 trading sessions since November 13, 2025, VIVI closed higher on 73 days (29%).
Its best day was December 8, 2025 (+27.14%) and its worst was August 27, 2026 (-22.50%).
The stock moved 10% or more in a single session 34 times.
It opened at least 5% above the previous day's high 19 times.
Recent signals
VIVI news
-
Nov 10, 2026:
TempraMed Granted U.S. Patent for Pen Agnostic, VIVI Cap Smart(TM) Further Strengthens Global Intellectual Property Position
-
Nov 2, 2026:
TempraMed Signs Exclusive UK Distribution Agreement with Poole Bay Holdings for VIVI Epi(TM), Targeting School Networks Across the UK
-
Oct 28, 2026:
TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina
-
Oct 20, 2026:
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
-
Oct 15, 2026:
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
-
Oct 8, 2026:
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
-
Oct 5, 2026:
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
-
Oct 1, 2026:
TempraMed Technologies Raises $1.2 Million Via Non-Brokered Private Placement
About TempraMed Technologies Ltd.
TempraMed develops patent protected technology designed to serve a broad range of medical and consumer products TempraMeds primary business focus is revolutionizing injectors for temperature sensitive medications by making them SMART and temperature protected
Similar stocks
Find more stocks like VIVI with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.